North Dakota State Investment Board Purchases New Shares in Cencora, Inc. $COR

North Dakota State Investment Board purchased a new stake in Cencora, Inc. (NYSE:COR) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 6,269 shares of the company’s stock, valued at approximately $2,117,000.

A number of other institutional investors have also made changes to their positions in the business. Elyxium Wealth LLC bought a new position in shares of Cencora in the fourth quarter valued at about $27,000. Rossmore Private Capital raised its holdings in shares of Cencora by 81.5% in the fourth quarter. Rossmore Private Capital now owns 1,548 shares of the company’s stock valued at $523,000 after buying an additional 695 shares during the last quarter. Millennium Capital Advisors LLC bought a new position in shares of Cencora in the fourth quarter valued at about $220,000. Lawood & Co. bought a new position in shares of Cencora in the fourth quarter valued at about $209,000. Finally, AlphaCore Capital LLC raised its holdings in shares of Cencora by 14.2% in the fourth quarter. AlphaCore Capital LLC now owns 2,000 shares of the company’s stock valued at $675,000 after buying an additional 249 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on COR shares. JPMorgan Chase & Co. lifted their price target on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Barclays lifted their price target on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. UBS Group lifted their price target on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Evercore set a $360.00 price objective on Cencora in a report on Wednesday, April 8th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $380.25.

Cencora Stock Performance

Shares of NYSE:COR opened at $262.15 on Tuesday. The stock has a market capitalization of $51.00 billion, a P/E ratio of 20.10, a P/E/G ratio of 1.19 and a beta of 0.64. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The business has a 50-day moving average price of $312.71 and a two-hundred day moving average price of $338.72.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts predict that Cencora, Inc. will post 17.76 earnings per share for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. Cencora’s payout ratio is currently 18.40%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.